Pharmacology is the science that explains how drugs interact with living systems to produce therapeutic or toxic effects. This chapter introduces pharmacology as a discipline distinct from pharmacy and organizes it around its two core pillars: pharmacokinetics (“what the body does to the drug”) and pharmacodynamics (“what the drug does to the body”). The LADME framework (liberation, absorption, distribution, metabolism, excretion) describes the time course of drug concentration, while receptor theory and dose–response relationships explain how that concentration is translated into effect. The chapter traces the evolution of modern pharmacology from descriptive materia medica to experimental science through the work of Buchheim and Schmiedeberg, and to rational drug design through Paul Ehrlich’s concepts of receptors and the “magic bullet.” It then broadens the scope to modern domains such as clinical pharmacology, toxicology, pharmacovigilance, and pharmacogenomics, highlighting how genetic variation shapes drug response and personalizes therapy. The nature and sources of drugs—natural, synthetic, semi-synthetic, and biologic—are outlined, as is the public health importance of the WHO Essential Medicines List. Principles of drug administration, including the impact of the hepatic first-pass effect and the choice of enteral vs. parenteral routes, are discussed in relation to bioavailability. Finally, the chapter reviews key pharmacodynamic phenomena—agonism, antagonism, spare receptors—and clinical variability in drug response, including tolerance, tachyphylaxis, dependence, idiosyncrasy, and immune-mediated hypersensitivity (Gell and Coombs Types I–IV). Together, these concepts form the foundational framework for understanding rational drug therapy. Keywords: pharmacology; pharmacokinetics (LADME); pharmacodynamics; receptor theory; dose–response; routes of drug administration; first-pass effect; essential medicines; pharmacogenomics; hypersensitivity reactions. 1.1 Defining the Discipline: The Science of Drug Action Pharmacology is the comprehensive scientific discipline that investigates the interactions of chemical substances with living systems. It is a field dedicated to understanding a substance's origin, composition, properties, mechanisms of action, therapeutic uses, and toxicology. At its core, pharmacology explores how an external (exogenous) chemical, known as a drug, can modify or regulate existing physiological and biochemical processes within an organism to achieve a therapeutic effect. It is critical to distinguish pharmacology, the science of drug action, from pharmacy , the profession concerned with the safe and effective preparation, preservation, and dispensing of those drugs. The vast discipline of pharmacology is traditionally and conceptually divided into two fundamental pillars: pharmacokinetics and pharmacodynamics. The Two Pillars: Pharmacokinetics and Pharmacodynamics Pharmacokinetics (PK) Pharmacokinetics is formally defined as the study of "what the body does to the drug". It is the branch of pharmacology concerned with the movement of drugs within the body, quantitatively describing the time course of a drug's journey.The principles of PK govern the concentration of a drug that ultimately reaches its site of action. This entire process is often summarized by the acronym LADME: ● Liberation: The initial step where the active pharmaceutical ingredient (API) is released from its pharmaceutical formulation (e.g., the dissolution of a tablet). ● Absorption: The process by which the drug moves from the site of administration into the bloodstream. ● Distribution: The reversible transfer of a drug from the bloodstream to and from various tissues and fluids of the body. ● Metabolism: The chemical transformation (biotransformation) of the drug by the body, primarily by enzymes in the liver, into new compounds (metabolites) that are typically easier to excrete. ● Excretion: The irreversible removal of the drug and its metabolites from the body, most commonly via the kidneys in urine, but also through bile, sweat, and exhaled air. Pharmacodynamics (PD) Pharmacodynamics is the counterpart to PK and is defined as the study of "what the drug does to the body". This field examines the biochemical and physiological effects of drugs and their mechanisms of action. Pharmacodynamics seeks to answer the fundamental questions of how and where a drug acts to produce its effect. Key concepts in pharmacodynamics include: ● Receptor Binding: The interaction of a drug with its specific molecular target, which is most often a protein receptor on a cell surface or inside a cell. ● Signal Transduction: The cascade of biochemical events that occurs after the receptor is activated, translating the drug-receptor binding event into a cellular response. ● Dose-Response Relationship: The mathematical relationship between the concentration of a drug (the dose) and the magnitude of the physiological effect it produces. ● Therapeutic Window: The range of drug doses that produces a therapeutic effect without causing significant toxicity. These two branches are not independent; they are inextricably linked in a continuous, dynamic cycle that forms the basis of therapeutic management. The goal of pharmacology is to control this dynamic process. Pharmacokinetic processes (LADME) determine the concentration of the drug at its site of action at any given time. This concentration, in turn, dictates the magnitude and duration of the pharmacodynamic effect (e.g., how many receptors are bound and for how long). Finally, the pharmacodynamic action is terminated as pharmacokinetic processes (metabolism and excretion) clear the drug from the body. This predictable link between the drug concentration in the plasma (a PK value that can be easily measured) and the drug concentration at the receptor site (a PD value that cannot be measured) is known as kinetic homogeneity . This principle is the foundational assumption of all therapeutic drug monitoring, allowing clinicians to use plasma levels as a proxy to guide dosing and achieve a desired therapeutic effect. Figure 1.1: The Dynamic Relationship between Pharmacokinetics and Pharmacodynamics 1.2 The Evolution of a Science: Historical Landmarks The study of how substances affect the body is ancient, but for millennia, it was a purely descriptive field known as materia medica —a catalog of medicinal plants and remedies. The transition of pharmacology into a modern, experimental science began in the 19th century. Rudolf Buchheim (1820-1879) is credited with moving the field beyond mere description. In 1847, he established the first institute of pharmacology (initially in the basement of his home in Dorpat, Estonia) and was the first to systematically use laboratory experimentation to understand how drugs interact with living organisms. Oswald Schmiedeberg (1838-1921) , a student of Buchheim, is widely recognized as the "Father of Modern Pharmacology". Schmiedeberg's singular contribution was the formalization of pharmacology as a distinct, respected, and independent academic discipline. In 1872, he established his own Institute of Pharmacology at the University of Strasbourg, which became the most important center for pharmacological research in the world. He trained hundreds of students from across the globe, who went on to establish pharmacology departments at their own universities, disseminating his rigorous, experimental approach. His own research on the actions of drugs like digitalis and muscarine, and his work on drug metabolism, set the standard for the new field. Paul Ehrlich (1854-1915) , a German physician and scientist, provided the next great conceptual leap. While Schmiedeberg founded the discipline of pharmacology (how to study drugs), Ehrlich established the goal of modern therapeutics (how to create drugs). His work transitioned the field from experimental pharmacology to rational drug design. Ehrlich's contributions were twofold: 1. Receptor Theory: Based on his work on bacterial toxins and immunity, Ehrlich postulated in the late 19th and early 20th century that for a chemical to exert any effect, it must first bind to a specific structure on the cell. He famously stated, " Corpora non agunt nisi fixata —A substance does not act unless it is bound." He visualized these binding sites as "side-chains" or "receptors" on the cell surface. This "lock and key" concept provided the fundamental theoretical framework for all of modern pharmacodynamics. 2. The "Magic Bullet": This concept, a direct consequence of his receptor theory, was the idea that one could synthesize a chemical compound—a "magic bullet"—that would be exquisitely toxic to a specific pathogen (e.g., a bacterium) by binding to its unique receptors, while leaving the host's healthy cells completely unharmed. Ehrlich's genius was not just in the theory; he proved it in practice. He and his colleague Sahachiro Hata embarked on a systematic quest to find a cure for syphilis. They synthesized and tested hundreds of arsenic compounds, culminating in 1909 with "compound 606," Salvarsan (arsphenamine). It was the first effective treatment for syphilis and the world's first true antimicrobial drug. This triumph was the birth of chemotherapy and the validation of rational drug discovery. This historical arc represents a profound intellectual shift from passive observation to active, predictive invention. Schmiedeberg's work was descriptive; he gave science the tools to analyze what drugs do. Ehrlich's work was predictive; his receptor theory provided the rational basis for designing new drugs for specific targets. This leap is the true origin of the modern pharmaceutical industry. 1.3 The Scope of Modern Pharmacology From the foundations laid by Schmiedeberg and Ehrlich, pharmacology has expanded into a vast and diverse field, encompassing numerous sub-disciplines. The scope of modern pharmacology is no longer limited to a single laboratory but spans from the level of molecular genetics to global public health. Key sub-disciplines include: ● Toxicology: The study of the adverse effects of chemicals on living systems. This includes not only drug toxicity and adverse drug reactions but also the mechanisms of action of poisons and environmental toxins. ● Clinical Pharmacology: The branch of pharmacology that applies basic principles to human subjects. It is the science of drugs in humans, focusing on efficacy, safety, and variability in clinical trials and direct patient care. ● Systems Pharmacology: These disciplines focus on the effects of drugs on specific organ systems. Examples include Neuropharmacology (drugs affecting the brain and nervous system), Cardiovascular Pharmacology (drugs affecting the heart and circulation), and Renal Pharmacology (drugs affecting the kidneys). ● Pharmacovigilance: A critical public health function, this is the science and practice of monitoring, detecting, assessing, and preventing adverse drug reactions (ADRs) after a drug has been approved and is on the market. The Personalization of Medicine: Pharmacogenomics Perhaps the most transformative modern field is pharmacogenomics, the study of how an individual's genetic makeup affects their response to drugs. This field is often used interchangeably with pharmacogenetics, which more narrowly studies the influence of single gene variations on drug response, whereas pharmacogenomics takes a broader, genome-wide approach. This discipline represents the ultimate refinement of modern therapeutics, moving away from the "one size fits all" dosing model. It addresses a fundamental problem in medicine: even our best drugs may only be effective in a fraction of the population and can cause severe toxicity in others. Pharmacogenomics explains this inter-individual variability by looking at our DNA. The clinical utility of pharmacogenomics is already established and growing rapidly 1. Predicting Response or Non-Response: Genetic testing can identify biomarkers that predict whether a patient will benefit from a specific drug. For example, in breast cancer, only patients whose tumors are Estrogen Receptor (ER) positive will respond to tamoxifen. Patients with colon cancer who have KRAS gene mutations will not respond to cetuximab. 2. Predicting Adverse Drug Reactions (ADRs): Genetic screening can identify patients at high risk for severe, life-threatening ADRs. A classic example is HLA-B gene testing. Patients with a specific HLA-B allele are at extremely high risk for a severe hypersensitivity syndrome (DRESS/SJS/TEN) if given drugs like abacavir or allopurinol. 3. Predicting Pharmacokinetics: Genetic variations in metabolic enzymes can determine whether a standard dose of a drug will be effective, toxic, or have no effect at all. For instance, testing for the TPMT enzyme before starting the drug azathioprine can identify "poor metabolizers." These patients are at high risk for severe, life-threatening bone marrow suppression (myelosuppression) from a standard dose and require a much lower dose. Pharmacogenomics is, in many ways, the modern fulfillment of Paul Ehrlich's "magic bullet." Ehrlich's original concept was about targeting the pathogen . Today, the challenge is often not the pathogen but the variability of the host . Pharmacogenomics refines the magic bullet by allowing for the "stratification of patients based on their genotype". It provides the tools to understand why a drug is a cure for Patient A but a poison for Patient B, allowing us to personalize the therapy for an individual's unique genetic landscape. 1.4 The Nature and Source of Drugs A drug is a chemical substance of known structure, other than a nutrient or an essential dietary ingredient, which, when administered to a living organism, produces a biological effect. The sources of these substances are as varied as nature itself and as complex as modern biotechnology. The science of identifying and studying drugs from natural origins is known as pharmacognosy . Natural Sources For most of human history, the pharmacy was the natural world. Drugs were derived directly from plants, animals, and minerals. ● Plant Source: This remains an incredibly rich source of new drug candidates. Almost all parts of a plant—leaves, roots, bark, fruits, and seeds—have yielded powerful medicines. ○ Examples: Morphine (a potent analgesic from the unripe fruit of the Papaver somniferum or opium poppy), Digoxin (a cardiac glycoside from the leaves of the Digitalis purpurea or purple foxglove plant), Paclitaxel (an anticancer drug first isolated from the bark of the Taxus brevifolia or Pacific yew tree), and Atropine (an anticholinergic from the Atropa belladonna or deadly nightshade plant). ● Animal Source: This involves the use of animal organs, glands, and secretions for their therapeutic compounds. ○ Examples: Insulin (historically extracted from the pancreas of cows and pigs), Thyroid hormone (from desiccated sheep thyroid glands), Human Chorionic Gonadotropin (hCG) (a fertility hormone extracted from urine), and Cod liver oil (a source of vitamins A and D). ● Microbial Source: The discovery that microorganisms produce chemicals to fight each other revolutionized medicine. ○ Examples: Penicillin (the first antibiotic, isolated from the fungus Penicillium notatum ), Streptomycin (from the bacterium Streptomyces griseus ), and Neomycin (from Streptomyces fradiae ). ● Mineral Source: These are simple inorganic elements and salts. ○ Examples: Ferrous sulfate (used to treat iron-deficiency anemia), Magnesium sulfate (used as a purgative and in pre-eclampsia), and Lithium carbonate (a mood stabilizer for bipolar disorder). Laboratory-Derived Drugs As chemistry advanced, scientists moved from simply extracting natural products to synthesizing new ones. ● Synthetic Drugs: These drugs are created entirely through chemical synthesis in a laboratory; they do not have a natural origin. The vast majority of modern medicines fall into this category. ○ Examples: Antihistamines , Antipyretics (e.g., paracetamol/acetaminophen), and many antibiotics like Ampicillin . ● Semi-Synthetic Drugs: These are hybrid drugs that bridge the natural and synthetic worlds. A natural product serves as the starting chemical scaffold, which is then modified in the lab to create a new compound with enhanced properties (e.g., greater potency, better absorption, or reduced side effects). ○ Examples: Heroin (diacetylmorphine) is a semi-synthetic drug made by chemically modifying morphine (from the opium poppy). Ampicillin is a semi-synthetic derivative of the natural 6-aminopenicillanic acid nucleus (from Penicillium ). Aspirin (acetylsalicylic acid) is a semi-synthetic derivative of salicin, a compound found in willow bark. The Biologic Revolution: Small Molecules vs. Large Molecules The most significant modern classification of drugs is not based on their origin (e.g., plant vs. synthetic) but on their size and complexity . This divides the entire pharmacopeia into two distinct classes: small molecules and large molecules (biologics). Small Molecule Drugs These are the "traditional" drugs that have dominated pharmacology for the past century. ● Properties: They are simple chemical compounds with a low molecular weight , typically less than kilodalton (kDa). Their chemical structure is simple, well-defined, and easily characterized. ● Production: They are manufactured using reproducible chemical synthesis in a laboratory or factory. ● Characteristics: They are generally shelf-stable (not sensitive to temperature) and, because of their small size, can often be designed to be absorbed through the gut, allowing for oral administration (pills). ● Examples: Aspirin, ibuprofen, antihistamines, and most oral antibiotics like penicillin. Large Molecule Drugs (Biologics) This is a newer and rapidly expanding class of therapeutics. ● Properties: They have a high molecular weight and are typically complex, heterogeneous proteins or polypeptides (e.g., composed of hundreds of amino acids). ● Production: Their complexity makes chemical synthesis impossible. Biologics must be produced by living systems . This is achieved using recombinant DNA technology, where genes for a human protein are inserted into bacteria (like E. coli ), yeast, or mammalian cells, which then act as "factories" to produce the desired protein. ● Characteristics: This complex production process is difficult to scale and expensive, and the resulting protein drugs are often unstable , requiring careful storage (e.g., refrigeration) and protection from shaking. Because they are large proteins, they cannot be taken orally (they would be digested in the stomach) and must be administered by injection or infusion . ● Examples: Recombinant Human Insulin , Viral Vaccine , and Monoclonal Antibodies (mAbs) . The development of monoclonal antibodies (mAbs) perfectly illustrates the evolution of biologics. The first therapeutic mAb (Muromonab-CD3, 1986) was fully murine (derived from mouse cells).However, the human immune system recognized it as foreign, limiting its use. Genetic engineering then allowed for the creation of "chimeric" (part-mouse, part-human) and "humanized" antibodies, which are now over 95% human in structure. This humanization significantly reduces the immune response and enhances the drug's efficacy. The distinction between small and large molecules is fundamental. A drug's source and size define its therapeutic reality, from its cost and stability to its route of administration. The primary trade-off is this: the large, complex structure of a biologic allows for exquisite target specificity (e.g., an antibody designed to bind to one unique cancer-cell protein), achieving effects that less-specific small molecules cannot. However, this same size and protein nature make it vulnerable to digestion (ruling out oral use) and far more complex and expensive to manufacture. Table 1.1: A Comparison of Small Molecule Drugs and Large Molecules (Biologics) Characteristic Small Molecules Large Molecules (Biologics) Molecular Weight Low (typically < kDa) High (often > kDa) Structure Simple, well-defined Complex, heterogeneous (e.g., proteins) Source/Production Chemical synthesis Living systems (e.g., mammalian cells, bacteria, yeast) using recombinant DNA technology Stability Generally high; often heat-stable Generally low; often sensitive to heat, light, and agitation Typical Administration Often oral (as pills, capsules) Injection or infusion only (e.g., subcutaneous, intravenous) Immunogenicity Generally low (too small to be seen by the immune system) High potential; can be recognized as "foreign" by the immune system Examples Aspirin, Paracetamol, Ampicillin, Statins Recombinant Insulin, Vaccines, Monoclonal Antibodies (e.g., Adalimumab) 1.5 The Essential Medicines Concept: A Global Public Health Imperative While the pharmaceutical industry develops thousands of drugs, not all are of equal value. The "open pharmaceutical market" is flooded with a large number of medicines, many of which may be of "doubtful value" or represent minor variations of existing drugs with no clear benefit.In response to this, and recognizing that limited health budgets must be spent wisely, the World Health Organization (WHO) introduced a transformative public health framework. Definition and History The WHO defines Essential Medicines as "those that effectively and safely treat the priority healthcare needs of the population". This concept was formalized in 1977 with the publication of the first WHO Model List of Essential Medicines (EML) . This initial list contained approximately medicines and was considered a major revolution in public health; it was the first global acknowledgment that "some medicines are more important than others". The Model List is now updated every two years by an expert committee, and since 2007, a separate Model List of Essential Medicines for Children (EMLc) has been published to address the unique needs of pediatric patients. Purpose and Public Health Impact The WHO Model List is not a global mandate; it is a guide or tool intended to help countries develop their own national essential medicines lists.Today, over countries have adopted this concept and created national EMLs. The EML concept is a "powerful tool to promote health equity". Its purpose is to impose evidence-based rationality onto the pharmaceutical market. By focusing on a "limited number" of carefully selected medicines, a country's health system can: ● Improve Quality of Care: Ensure that the most effective and safe medicines are available for the most common diseases. ● Promote Rational Prescribing: Discourage the use of drugs with doubtful efficacy or poor safety profiles. ● Control Costs: Streamline procurement, distribution, and reimbursement, focusing limited financial resources on the medicines that provide the best value. Selection Criteria The selection of a drug for the EML is not arbitrary. It is a rigorous, evidence-based process. The WHO Expert Committee selects medicines based on three primary criteria 1. Public Health Relevance: The drug must address a priority health need of the population, based on disease prevalence. 2. Efficacy and Safety: There must be solid scientific evidence from controlled clinical trials and/or epidemiological studies demonstrating that the drug is both effective and safe. 3. Comparative Cost-Effectiveness: When multiple drugs are available for the same condition, the one with the best cost-effectiveness profile (i.e., the best value for the cost) is selected. When two drugs are therapeutically equivalent, preference is given to the one that has been most thoroughly investigated, has the most favorable pharmacokinetic properties, and has favorable stability under the storage conditions available. Single-compound formulations are strongly preferred. Fixed-ratio combination products (a pill with two or more drugs) are only accepted if the combination has a proven advantage over the single compounds in terms of therapeutic effect, safety, or patient adherence. In recent years, this concept has evolved. A drug's "essentiality" (high clinical need) must also be considered alongside its "vulnerability" (a fragile supply chain).A drug that is essential but prone to shortages requires a different public health strategy than one that is essential and widely available. This ensures the EML concept remains a practical tool not just for selecting drugs, but for securing them. 1.6 Principles of Drug Administration: Routes and Bioavailability For a drug to produce a pharmacodynamic effect, it must first reach its target site in a sufficient concentration. The method of administration—the route of administration —is the first and most critical factor a clinician controls to determine a drug's pharmacokinetic profile, influencing its speed of onset and its bioavailability. Routes are broadly classified based on their target of action and where they are applied ● Topical: Applied to a surface (like skin, eyes, or nose) for a local effect. ● Enteral: Delivered via the gastrointestinal (GI) tract for a systemic effect (i.e., to be absorbed into the blood). ● Parenteral: Delivered by any route other than the GI tract (typically by injection) for a systemic effect. The Enteral Routes These routes involve the GI tract and are the most common. ● Oral (PO): The drug is swallowed as a liquid, capsule, or tablet. This is the most common, convenient, safe, and inexpensive route. However, it has significant limitations: absorption can be slow and variable (affected by food, pH, and GI motility), some drugs are destroyed by stomach acid, and others can irritate the GI lining. ● Sublingual (SL) / Buccal: The drug is placed under the tongue (sublingual) or between the gum and cheek (buccal) to dissolve. Its main advantage is that it avoids the GI tract. The rich blood supply in the oral mucosa allows for rapid absorption directly into the systemic circulation. ● Rectal (PR): The drug is administered as a suppository into the rectum. This is a practical alternative for patients who are unconscious, actively vomiting, or for infants. The walls of the rectum are highly vascularized, allowing for rapid and effective absorption. The Hepatic First-Pass Effect (Presystemic Metabolism) The primary challenge for the oral route is the first-pass effect , also known as presystemic metabolism. ● Definition: When a drug is absorbed from the stomach or small intestine, the blood from these organs does not go directly into the general (systemic) circulation. Instead, it collects in the hepatic portal vein and is delivered first to the liver . ● Mechanism: The liver (and to a lesser extent, the gut wall) is the body's primary metabolic center. It is rich in enzymes (such as the Cytochrome P450 family) that are designed to chemically alter foreign substances. As the newly absorbed drug passes through the liver, a significant fraction of it may be metabolized (inactivated) before it ever has a chance to reach its target site . ● Consequence: This effect dramatically reduces the bioavailability of the drug—the fraction of the administered dose that reaches the systemic circulation. For drugs with a high first-pass effect (e.g., propranolol, lidocaine, morphine, nitroglycerin), the oral bioavailability is very low. This means the oral dose must be much, much higher than the intravenous dose to achieve the same therapeutic effect. Choosing a route of administration is therefore a strategy to control this effect. The sublingual and rectal routes are effective because they bypass (or partially bypass) the portal circulation, draining directly into systemic veins, thus avoiding the first-pass effect. Figure 1.2: Routes of Drug Administration and the First-Pass Effect The Parenteral Routes These routes involve administration by injection, bypassing the GI tract entirely.They are used when rapid onset is required, when drugs are poorly absorbed or unstable in the GI tract (like biologics), or when the patient cannot take oral medication. ● Intravenous (IV): The drug is injected directly into a vein. ○ Advantages: This is the most rapid and predictable route. It provides 100% bioavailability and an immediate effect (onset in 30-60 seconds). It allows for precise dose control, as the infusion can be stopped instantly. ○ Disadvantages: It is the most dangerous route. The drug cannot be recalled once injected. It requires sterile technique, can be difficult to administer, and carries a higher risk of infection or adverse effects from rapid delivery. ● Intramuscular (IM): The drug is injected into a large muscle (e.g., deltoid, ventrogluteal). ○ Advantages: Absorption is faster than oral (onset 10-20 minutes) and more reliable. It can also be used for "depot" formulations, where the drug is suspended in an oily vehicle and slowly leaches out, providing a therapeutic effect for weeks or months. ● Subcutaneous (SC): The drug is injected into the adipose (fatty) tissue just beneath the skin. ○ Advantages: Absorption is slower than IM (onset 15-30 minutes), providing a more sustained effect. It is a simple injection to perform, making it ideal for patient self-administration (e.g., insulin for diabetes). Figure 1.3: Parenteral Injection Techniques Other Major Routes ● Inhalation: The drug is aerosolized into fine droplets and breathed into the lungs. ○ Advantages: This route offers an extremely rapid onset of action (2-3 minutes), rivaling the IV route. The lungs have an enormous surface area and rich blood supply, allowing for near-instantaneous absorption into the bloodstream. It also bypasses the first-pass effect. ● Transdermal: The drug is applied to the skin (usually via a patch) with the intent of being absorbed for a systemic effect. ○ Advantages: This route is ideal for slow, sustained, and continuous drug delivery over a long period (hours to days). It provides stable plasma concentrations and bypasses the first-pass effect. Table 1.2: Comparison of Major Routes of Drug Administration Route Onset of Action Bioavailability (BioA.) Advantages Disadvantages Oral (PO) Slow (30-90 min) Variable (<100%) Most common, convenient, safe, and economical Variable absorption; subject to first-pass effect; GI irritation Sublingual (SL) Fast (3-5 min) High (<100%) Rapid absorption; bypasses first-pass effect ; convenient Must not be swallowed; unpalatable drugs are difficult to use Rectal (PR) Variable (5-30 min) Variable (50-100%) Useful in vomiting or unconscious patients; partially bypasses Absorption can be irregular; potential for rectal irritation first-pass effect Intravenous (IV) Immediate (30-60 sec) 100% (by definition) Rapid onset; precise dose control; bypasses first-pass effect Most dangerous route; irreversible; requires sterile technique; risk of infection Intramuscular (IM) Fast (10-20 min) High (<100%) Good for depot formulations; faster than oral Can be painful; risk of nerve injury; requires sterile technique Subcutaneous (SC) Slow (15-30 min) High (<100%) Good for self-administrat ion (e.g., insulin); slow, sustained release Slower onset than IM; small volumes only; can cause local irritation Inhalation Very Fast (2-3 min) High (<100%) Very rapid onset; bypasses first-pass effect ; good for local or systemic effects Requires patient coordination; can be irritating to lungs Transdermal Very Slow (min to hours) High (<100%) Slow, sustained release; stable plasma levels; bypasses Slow onset; only for lipid-soluble drugs; can first-pass effect cause skin irritation 1.7 Fundamentals of Pharmacodynamics: How Drugs Act Once a drug has been delivered to its site of action (a pharmacokinetic process), its pharmacodynamic effect begins. As Paul Ehrlich first proposed, most drugs produce their effects by binding to specific molecular targets, which are typically large protein molecules called receptors . The drug-receptor interaction is governed by two fundamental properties: 1. Affinity: This describes the "strength" of the binding between a drug and its receptor.A drug with high affinity binds tightly to the receptor, even at low concentrations. 2. Intrinsic Activity (or Efficacy): This is the ability of a drug, after it has bound to the receptor, to activate that receptor and produce a change in cell function that leads to a biological response. Drugs are classified based on their combination of affinity and intrinsic activity. Agonists: Generating a Response An agonist is a drug that binds to a receptor and activates it, producing a biological response. Agonists possess both affinity and intrinsic activity. They mimic the effect of the body's own endogenous ligands (like hormones or neurotransmitters). Full Agonists A full agonist is a drug with high intrinsic efficacy.63 When it binds to the receptor, it produces a maximal biological response (100% effect) that the system is capable of.60 A full agonist can typically produce this maximal response while occupying only a low proportion of the available receptors. ● Example: Morphine is a full agonist at the mu-opioid receptor. It binds and activates these receptors to their full potential, producing strong analgesia. Partial Agonists A partial agonist is a drug with lower intrinsic efficacy.63 It binds to the receptor (it has affinity) but produces only a submaximal response, even when 100% of the receptors are occupied. Its maximal effect is, by definition, lower than that of a full agonist. ● Clinical Example: Buprenorphine , used to treat opioid addiction, is a classic partial agonist at the mu-opioid receptor. This partial activation is the key to its therapeutic profile. It produces a weaker opioid effect (e.g., euphoria, respiratory depression) than full agonists like heroin or methadone. This creates a "ceiling effect": at higher doses, its effects plateau rather than continuing to increase, which significantly lowers the risk of fatal overdose. ● The Dual Property: Because a partial agonist competes with a full agonist for the same receptor, it can also act as an antagonist . If a patient takes buprenorphine (a partial agonist), its high affinity allows it to bind to the mu-receptors and displace other opioids like heroin or methadone (full agonists).By replacing a high-efficacy agonist with a low-efficacy one, it blocks the full agonist's effect. Antagonists: Blocking a Response An antagonist is a drug that attenuates or blocks the action of an agonist. It binds to the receptor (it possesses affinity) but has zero intrinsic activity. It produces no effect on its own; its only action is to prevent an agonist (either an endogenous ligand or another drug) from binding and activating the receptor. Antagonists are primarily divided into two classes based on their mechanism of interaction. Competitive Antagonist (Reversible) ● Mechanism: A competitive antagonist binds reversibly to the exact same binding site (the active site) as the agonist. The agonist and antagonist are in direct competition for this single site, and their binding is mutually exclusive. ● Effect: This type of blockade is surmountable . Because the binding is reversible, the "winner" of the competition is determined by concentration. By increasing the concentration of the agonist, the antagonist's blockade can be overcome, and the maximal effect of the agonist can still be achieved. Non-Competitive Antagonist ● Mechanism: A non-competitive antagonist prevents the agonist's action in a way that is insurmountable —that is, increasing the agonist concentration cannot restore the maximal effect. ● This can occur via two primary mechanisms: 1. Allosteric Antagonism: The antagonist binds to an allosteric site (a different, non-agonist site) on the receptor. This binding induces a conformational change (a change in the receptor's shape) that either prevents the agonist from binding to the active site or prevents the receptor from activating, even if the agonist is bound. 2. Irreversible Antagonism: The antagonist binds to the active site, just like a competitive antagonist, but does so irreversibly (e.g., by forming a stable, covalent bond). This permanently removes that receptor from the available pool. ● Examples: Ketamine is a non-competitive antagonist of the NMDA receptor (an allosteric mechanism). Phenoxybenzamine is an irreversible antagonist that binds covalently to alpha-adrenergic receptors. The Concept of Spare Receptors In many biological systems, a maximal response (Emax) can be achieved when the agonist is occupying only a fraction of the total available receptors.The receptors that are "left over" and not needed to achieve this full effect are called spare receptors or a "receptor reserve". ● Significance: The existence of spare receptors is a powerful mechanism for signal amplification . It means the tissue is highly sensitive to the agonist. For example, in cardiomyocytes (heart muscle cells), less than 10% of $\beta$-adrenergic receptors need to be stimulated by catecholamines to elicit the maximal effect. ● Pharmacological Consequence: Because of this amplification, the concentration of agonist needed to produce 50% of the maximal effect (the $EC_{50}$ ) is often much lower than the concentration of agonist needed to bind 50% of the receptors (the $K_d$ ). This increases the apparent potency and sensitivity of the tissue to the drug. ● Clinical Relevance: The number of spare receptors can vary dramatically between different tissues. This explains why a drug may act as a full agonist in a tissue with a high receptor reserve (like the heart) but only as a partial agonist in a tissue with few or no spare receptors for that same drug. This concept of a receptor reserve also introduces a crucial nuance to understanding antagonists. In a system with spare receptors, a non-competitive antagonist will, at low doses, primarily bind to and inactivate the spare receptors. Since these receptors were not needed for a maximal response anyway, the Emax of the agonist will be unchanged . The dose-response curve will simply shift to the right, looking identical to that of a competitive antagonist. Only after all spare receptors have been exhausted by the non-competitive antagonist will any further dose begin to suppress the maximal effect. Therefore, the graphical "fingerprint" of an antagonist is not just a property of the drug, but a reflection of the receptor reserve in the specific tissue being tested. Visualizing Drug Action: Interpreting Dose-Response Relationships These pharmacodynamic concepts are best visualized using semi-logarithmic dose-response curves , which plot the drug concentration (on a log scale, $x$-axis) against the pharmacological response (on a linear scale, $y$-axis). Figure 1.4: Graded Dose-Response Curves (Agonists) Figure 1.5: Agonist Dose-Response in the Presence of Antagonists 1.8 Variability in Drug Response A major challenge in pharmacology and clinical medicine is the variability in drug response. A standard dose of a drug does not produce the same effect in all patients, or even in the same patient at all times. This variability can be broadly classified into phenomena of diminished response (tolerance, tachyphylaxis), complex neurobehavioral responses (dependence, addiction), and unpredictable adverse reactions (idiosyncrasy, allergy). Diminished Response: Tolerance vs. Tachyphylaxis These terms describe when a drug's effect lessens over time, but they are distinguished by their time course and mechanism. Tolerance Tolerance is a gradual decrease in the responsiveness to a drug following repeated or chronic administration. To achieve the same effect, the dose must be progressively increased.78 This process typically develops over days, weeks, or months.80 There are two primary mechanisms of tolerance: 1. Metabolic (Pharmacokinetic) Tolerance: The body adapts by becoming more efficient at eliminating the drug. Chronic drug exposure can cause enzyme induction , where the body produces more of the liver enzymes (e.g., CYP450s) responsible for metabolizing the drug. As a result, the drug is cleared from the blood faster, its half-life is shorter, and more drug is needed to maintain a therapeutic concentration. This is a common mechanism in chronic alcohol consumption. 2. Pharmacodynamic Tolerance: This is an adaptation at the cellular or receptor level. The body's cells attempt to restore homeostasis in the face of continuous drug stimulation. ○ Down-regulation: In response to a chronic agonist, the cell may physically reduce the number of receptors on its surface, giving the drug fewer targets to bind to. ○ Desensitization: The receptors that remain may become "uncoupled" from their intracellular signaling pathways (e.g., via phosphorylation), so that even when the agonist binds, no signal is produced. Tachyphylaxis Tachyphylaxis is a rapid (tachy-) decrease in drug response.80 It can develop very quickly, sometimes over minutes to hours, and occasionally after only one or two doses. ● Mechanism: Tachyphylaxis is too fast to be caused by enzyme induction or receptor down-regulation. It is most often caused by the depletion of an endogenous substance that the drug requires to exert its effect. ● Classic Example: The indirect sympathomimetic drug ephedrine works by entering nerve terminals and displacing the neurotransmitter noradrenaline from its storage vesicles, forcing its release. This release of noradrenaline causes the desired effect (e.g., increased blood pressure). If ephedrine is given in repeated, frequent doses, the nerve terminal's stores of noradrenaline become depleted. With no more noradrenaline to release, ephedrine stops working, and tachyphylaxis has occurred. Dependence, Addiction, and Tolerance: Deconstructing Complex Terminology These three terms are frequently and incorrectly used interchangeably. They describe distinct phenomena, and the distinction is critical for patient care. ● Tolerance: As defined above, this is a pharmacological phenomenon where a higher dose is needed to produce the same effect. ● Physical Dependence: This is a physiological state. It occurs as a result of physiological adaptations to chronic exposure to a drug. The body has reset its homeostasis to require the drug's presence to function "normally." The defining feature of physical dependence is that abruptly stopping or reducing the dose will precipitate an unpleasant physical withdrawal syndrome . This is a normal, predictable physiological response to many classes of drugs (e.g., opioids, beta-blockers, antidepressants). ● Addiction (Substance Use Disorder): This is a neurobehavioral disease . It is a chronic, relapsing disorder defined by compulsive drug seeking and use, despite negative and harmful consequences . It involves long-term changes in brain circuitry, particularly in reward and self-control pathways. Critical Distinction: Physical dependence is not addiction. A patient with severe chronic pain who takes prescribed morphine for months will develop both tolerance (needing a higher dose) and physical dependence (they will suffer withdrawal if they stop cold-turkey). This is a normal, expected physiological adaptation and does not mean the patient is addicted. Addiction is defined by the behaviors of compulsive use, loss of control, and use despite harm. Conversely, a person can be severely addicted to a drug (e.g., cocaine) that does not produce a medically severe, life-threatening physical withdrawal syndrome, demonstrating that addiction can exist without major physical dependence. Conflating these terms leads to the stigmatization and "punitive treatment of patients" who are simply experiencing a predictable physiological response to their necessary medication. Adverse Drug Reactions (ADRs): Idiosyncrasy vs. Allergy Adverse drug reactions (ADRs) are unwanted or harmful effects of drugs. They can be predictable (e.g., a known side effect) or unpredictable. Idiosyncrasy and allergy are two types of unpredictable ADRs. Idiosyncratic Reactions An idiosyncratic reaction is an abnormal, qualitatively aberrant reaction to a drug that is peculiar to a small subset of individuals. It is not an immune-mediated reaction. ● Mechanism: These reactions are typically caused by an underlying, often unknown, genetic anomaly in the patient. This genetic difference may be in a metabolic enzyme or a receptor. ● Classic Example: Drug-induced hemolytic anemia in patients with a genetic deficiency of the enzyme Glucose-6-Phosphate Dehydrogenase (G6PD) . G6PD is an enzyme that protects red blood cells from oxidative stress. When a G6PD-deficient individual takes an oxidative drug (like the antimalarial primaquine or the antibiotic dapsone), their red blood cells cannot cope with the oxidative stress, and they rupture (hemolysis), leading to severe anemia. This is not an allergy; it is a genetically determined metabolic failure. Drug Allergy (Hypersensitivity) A drug allergy is an adverse reaction caused by an immune-mediated response to a drug or its metabolites. The drug acts as an antigen (or, more commonly, a hapten that binds to a host protein). This type of reaction requires a prior sensitization exposure, where the immune system first "learns" to recognize the drug as foreign. Upon re-exposure, the immune system mounts an attack, which causes the tissue damage and symptoms. The Gell and Coombs Classification of Hypersensitivity Drug allergies, like all hypersensitivity reactions, are classified by their immune mechanism using the Gell and Coombs classification . ● Type I: Immediate / Anaphylactic Reaction ○ Mechanism: IgE-mediated . During sensitization, the body creates drug-specific IgE antibodies, which attach to the surface of mast cells and basophils. Upon re-exposure, the drug cross-links these IgE antibodies, causing the mast cell to degranulate and instantly release a flood of inflammatory mediators (e.g., histamine , leukotrienes). ○ Timing: Immediate (seconds to minutes). ○ Clinical Examples: Anaphylaxis from penicillin (a life-threatening reaction with bronchospasm and hypotension), urticaria (hives), and allergic rhinitis. ● Type II: Cytotoxic Reaction ○ Mechanism: IgG or IgM antibody-mediated . Antibodies are directed against cell-surface antigens . The drug may bind to the surface of a cell (e.g., a red blood cell), and the antibody attacks the drug-cell complex. This leads to cell destruction via complement activation or antibody-dependent cell-mediated cytotoxicity (ADCC). ○ Timing: Variable (hours to days). ○ Clinical Examples: Drug-induced hemolytic anemia (distinct from the G6PD mechanism), drug-induced autoimmune thrombocytopenia (destruction of platelets). ● Type III: Immune Complex Reaction ○ Mechanism: Immune complex-mediated . Circulating antigen-antibody ( IgG ) complexes form in the blood. These complexes are not cleared efficiently and become deposited in tissues, particularly the walls of small blood vessels, the joints, and the kidneys. The deposited complexes activate complement and recruit neutrophils, which release lytic enzymes and cause inflammatory tissue damage. ○ Timing: Variable (hours to days). ○ Clinical Examples: Serum sickness , drug-induced vasculitis (inflammation of blood vessels), and drug-induced systemic lupus erythematosus. ● Type IV: Delayed-Type / T-Cell-Mediated Reaction ○ Mechanism: T-cell-mediated . This type of allergy is not mediated by antibodies. It is a cellular immune response. Sensitized T-lymphocytes are activated by the drug (which is presented by antigen-presenting cells), leading to the release of inflammatory cytokines and a direct cytotoxic T-cell response. ○ Timing: Delayed (peaks 48-72 hours after re-exposure). ○ Clinical Examples: Contact dermatitis (e.g., from a topical antibiotic cream), the Mantoux tuberculin skin test. This mechanism is also responsible for some of the most severe and life-threatening ADRs, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) , which involve widespread keratinocyte (skin cell) apoptosis and skin sloughing. To manage this complex terminology, it is useful to separate these concepts along three "axes of differentiation." 1. Time Axis: Tachyphylaxis (rapid, hours) is distinguished from Tolerance (slow, weeks). 2. Mechanism Axis: Is the unpredictable reaction immune-mediated? If Yes , it is an Allergy . If No , and it is caused by a genetic defect, it is an Idiosyncrasy . 3. Domain Axis: Is the phenomenon primarily physiological/pharmacological? If Yes , it is Tolerance or Physical Dependence . Is it primarily behavioral? If Yes , it is Addiction . Figure 1.6: The Gell and Coombs Classification of Hypersensitivity Reactions 1.9 Chapter Summary and Key Concepts This chapter has introduced the foundational principles of pharmacology, the science of drug action. The key concepts to retain are: ● Pharmacology is the science of drug action, which is divided into two main branches. ● Pharmacokinetics (PK) is "what the body does to the drug" and is described by the processes of L iberation, A bsorption, D istribution, M etabolism, and E xcretion (LADME). ● Pharmacodynamics (PD) is "what the drug does to the body," describing its mechanism of action and dose-response relationship. PK determines the concentration, and PD determines the effect at that concentration. ● Oswald Schmiedeberg is the "Father of Modern Pharmacology" for formalizing it as a rigorous, experimental discipline. Paul Ehrlich provided the core concepts of "receptor theory" and the "magic bullet," which form the basis of rational drug discovery. ● Drugs are classified by origin (plant, animal, mineral, synthetic) and, more importantly, by structure. Small molecules are simple, synthetic, and often oral. Biologics (large molecules) are complex proteins produced by living systems and must be injected. ● The WHO Essential Medicines List (EML) is a public health tool used by nations to select a limited number of drugs based on public health relevance, efficacy, safety, and cost-effectiveness, thereby promoting rational prescribing and health equity. ● The Route of Administration is the primary tool for controlling a drug's PK profile. The hepatic first-pass effect describes the metabolic inactivation of an oral drug in the liver before it reaches the systemic circulation, which reduces its bioavailability. ● Routes such as Intravenous (IV) , Sublingual (SL) , and Transdermal bypass the first-pass effect, allowing for higher bioavailability. ● A Full Agonist has high intrinsic activity and produces a maximal effect. A Partial Agonist has lower intrinsic activity, produces a submaximal effect, and can act as an antagonist in the presence of a full agonist. ● A Competitive Antagonist binds reversibly to the active site and its effect is surmountable . A Non-Competitive Antagonist binds irreversibly or at an allosteric site, and its effect is insurmountable . ● Spare Receptors are a mechanism of signal amplification, allowing a maximal response to be produced when only a fraction of receptors are occupied. This increases the tissue's sensitivity to an agonist. ● Tolerance is a gradual decrease in drug effect (days/weeks) due to metabolic or receptor changes. Tachyphylaxis is a rapid decrease (minutes/hours) due to the depletion of an endogenous substance. ● Physical Dependence is a physiological state defined by a withdrawal syndrome. Addiction is a neurobehavioral disease defined by compulsive use despite harm. They are not the same. ● Idiosyncrasy is an unpredictable, abnormal drug reaction caused by a genetic defect (e.g., G6PD deficiency). ● Allergy (Hypersensitivity) is an unpredictable, adverse reaction caused by an immune system response (e.g., IgE, IgG, or T-cells) and is classified into Types I, II, III, and IV. References 1. A brief history of pharmacology | PPTX - Slideshare, accessed on November 4, 2025, https://www.slideshare.net/slideshow/a-brief-history-of-pharmacology/129466563 2. Pharmacology - Wikipedia, accessed on November 4, 2025, https://en.wikipedia.org/wiki/Pharmacology 3. The Role of Pharmacology in Modern Medicine: From Drug Discovery to Clinical Applications - Open Access Journals, accessed on November 4, 2025, https://www.openaccessjournals.com/articles/the-role-of-pharmacology-in-modern-medicine-from-drug- discovery-to-clinical-applications-16220.html 4. accessed on November 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK507791/#:~:text=Pharmacodynamics%20and%20pharmacokin etics%20are%20the,organism%20has%20on%20the%20drug. 5. Pharmacodynamics - StatPearls - NCBI Bookshelf - NIH, accessed on November 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK507791/ 6. The Difference Between Pharmacokinetics and Pharmacodynamics - BioAgilytix, accessed on November 4, 2025, https://www.bioagilytix.com/blog/the-difference-between-pharmacokinetics-and-pharmacodynamics/ 7. Chapter Pharmacokinetics & Pharmacodynamics - Nursing Pharmacology - NCBI - NIH, accessed on November 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK595006/ 8. Introduction to Pharmacokinetics and Pharmacodynamics - ASHP, accessed on November 4, 2025, https://www.ashp.org/-/media/store%20files/p2418-sample-chapter-1.pdf 9. an early history of the british pharmacological society, accessed on November 4, 2025, https://www.bps.ac.uk/getmedia/151d21c7-b759-4f60-bf90-d533f6eef321/Early-History-of-the-British-P harmacological-Society.pdf.aspx 10. A Historical Overview of Pharmacology | Carrington College, accessed on November 4, 2025, https://carrington.edu/blog/a-historical-overview-of-pharmacology/ 11. The Contributions of Paul Ehrlich to Pharmacology: A Tribute on the ..., accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2790789/ 12. A brief history of pharmacology - American Chemical Society, accessed on November 4, 2025, https://pubsapp.acs.org/subscribe/archive/mdd/v04/i05/html/05timeline.html 13. Explore Pharmacology - Boonshoft School of Medicine, accessed on November 4, 2025, https://medicine.wright.edu/sites/medicine.wright.edu/files/page/attachments/ExplorePharmacology_201 4.pdf 14. Role of pharmacogenomics in drug discovery and development - PMC - NIH, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2792612/ 15. Pharmacogenomics: A Genetic Approach to Drug Development and Therapy - PMC, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11279827/ 16. Introduction to Pharmacogenomics - Clinical Pharmacology & Toxicology Pearl of the Week - University of Calgary, accessed on November 4, 2025, https://cumming.ucalgary.ca/sites/default/files/teams/127/Intro%20to%20PGx%20June%202020.pdf 17. Pharmacognosy: Science of natural products in drug discovery - PMC - PubMed Central, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4204033/ 18. Plant-Derived Natural Products: A Source for Drug Discovery and Development - MDPI, accessed on November 4, 2025, https://www.mdpi.com/2813-2998/3/1/11 19. Drug development: Lessons from nature - PMC - NIH, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5449954/ 20. Nature and Source of Drugs | Pharmaguideline, accessed on November 4, 2025, https://www.pharmaguideline.com/2021/09/nature-and-source-of-drugs.html 21. Various sources of drugs - plant, animal, mineral, microbial | DOCX - Slideshare, accessed on November 4, 2025, https://www.slideshare.net/slideshow/various-sources-of-drugs-plant-animal-mineral-microbial/1264946 22. THE SYNTHETIC DRUG PHENOMENON - Unodc, accessed on November 4, 2025, https://www.unodc.org/res/WDR-2023/WDR23_B3_CH1_Synthetic_drugs.pdf 23. Semi-synthetic drugs - (Intro to Pharmacology) - Vocab, Definition, Explanations | Fiveable, accessed on November 4, 2025, https://fiveable.me/key-terms/introduction-to-pharmacology/semi-synthetic-drugs 24. Semi-synthetic Chemical Medicines - EUPATI Open Classroom, accessed on November 4, 2025, https://learning.eupati.eu/mod/book/tool/print/index.php?id=228 25. UNDERSTANDING CLANDESTINE SYNTHETIC DRUGS - Unodc, accessed on November 4, 2025, https://www.unodc.org/pdf/report_2001-06-26_1/analysis_clandestine.pdf 26. Ampicillin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed on November 4, 2025, https://go.drugbank.com/drugs/DB00415 27. Ampicillin | C16H19N3O4S | CID 6249 - PubChem - NIH, accessed on November 4, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Ampicillin 28. Aspirin - Wikipedia, accessed on November 4, 2025, https://en.wikipedia.org/wiki/Aspirin 29. What are the drugs of the future? - PMC - NIH, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6072476/ 30. Introduction to small molecule drug discovery and preclinical development - Frontiers, accessed on November 4, 2025, https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2023.1314077/full 31. accessed on November 4, 2025, https://www.allucent.com/resources/blog/points-consider-drug-development-biologics-and-small-molecu les#:~:text=Compared%20to%20biologics%2C%20small%20molecule,or%201%20kilodalton%20%5B kDa%5D. 32. Difference Between Small Molecule and Large Molecule Drugs - Caris Life Sciences, accessed on November 4, 2025, https://www.carislifesciences.com/difference-between-small-molecule-and-large-molecule-drugs/ 33. Defining the difference: What Makes Biologics Unique - PMC, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3564302/ 34. Drugs obtained by biotechnology processing - SciELO, accessed on November 4, 2025, https://www.scielo.br/j/bjps/a/JdZpw4JcNnZyHvL7BBp5Cpv/?format=pdf&lang=en 35. Biotechnology and genetic engineering in the new drug development. Part II. Monoclonal antibodies, modern vaccines and gene therapy - PubMed, accessed on November 4, 2025, https://pubmed.ncbi.nlm.nih.gov/24399705/ 36. Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies - PMC - NIH, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10759153/ 37. Monoclonal Antibodies: Historical Perspective and Current Trends in Biological Drug Development - MDPI, accessed on November 4, 2025, https://www.mdpi.com/1422-0067/26/18/8794 38. Technological advancement in the development of monoclonal antibody therapies: Present, past, and future, accessed on November 4, 2025, https://jabonline.in/admin/php/uploads/1222_pdf.pdf 39. Concept of Essential Medicines and Rational Use in Public Health ..., accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2888334/ 40. Essential medicines - World Health Organization (WHO), accessed on November 4, 2025, https://www.who.int/news-room/fact-sheets/detail/essential-medicines 41. WHO Model Lists of Essential Medicines - World Health Organization (WHO), accessed on November 4, 2025, https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-me dicines-lists 42. Essential medicines WPRO - World Health Organization (WHO), accessed on November 4, 2025, https://www.who.int/westernpacific/health-topics/essential-medicines 43. WHO Model List of Essential Medicines - Wikipedia, accessed on November 4, 2025, https://en.wikipedia.org/wiki/WHO_Model_List_of_Essential_Medicines 44. The selection and use of essential medicines, 2025 - World Health Organization (WHO), accessed on November 4, 2025, https://www.who.int/publications/i/item/B09474 45. Essential medicines concept for quality assurance of health care facilities - PMC - NIH, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3341722/ 46. WHO Criteria on the Selection of Essential Drugs - Healthy Documents, accessed on November 4, 2025, https://www.healthydoc.waba.org.my/public/doc21.html 47. Decision criteria for selecting essential medicines and their connection to guidelines: an interpretive descriptive qualitative interview study - PubMed, accessed on November 4, 2025, https://pubmed.ncbi.nlm.nih.gov/36584732/ 48. Managing medicine selection, accessed on November 4, 2025, https://msh.org/wp-content/uploads/2013/04/mds3-ch16-selection-mar2012.pdf 49. Which Drugs Should Be on the Essential Medicines List? - AMA Journal of Ethics, accessed on November 4, 2025, https://journalofethics.ama-assn.org/article/which-drugs-should-be-essential-medicines-list/2024-04 50. Route of administration - Wikipedia, accessed on November 4, 2025, https://en.wikipedia.org/wiki/Route_of_administration 51. Drug Administration - Drugs - MSD Manual Consumer Version, accessed on November 4, 2025, https://www.msdmanuals.com/home/drugs/administration-and-kinetics-of-drugs/drug-administration 52. ROUTES OF DRUG ADMINISTRATION, accessed on November 4, 2025, https://romanpub.com/resources/ijpsr%20v11-2020-7.pdf 53. Medication Routes of Administration - StatPearls - NCBI Bookshelf, accessed on November 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK568677/ 54. Drug Administration - Drugs - Merck Manual Consumer Version, accessed on November 4, 2025, https://www.merckmanuals.com/home/drugs/administration-and-kinetics-of-drugs/drug-administration 55. Physiological and Pharmaceutical Considerations for Rectal Drug Formulations - PMC, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6805701/ 56. First-pass metabolism - (Intro to Pharmacology) - Vocab, Definition, Explanations | Fiveable, accessed on November 4, 2025, https://fiveable.me/key-terms/introduction-to-pharmacology/first-pass-metabolism 57. First pass effect - Wikipedia, accessed on November 4, 2025, https://en.wikipedia.org/wiki/First_pass_effect 58. Chapter Administration of Parenteral Medications - Nursing Skills - NCBI Bookshelf, accessed on November 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK593214/ 59. Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity - PMC, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6165953/ 60. What is the difference between full agonists, partial agonists, and inverse agonists? - Patsnap Synapse, accessed on November 4, 2025, https://synapse.patsnap.com/article/what-is-the-difference-between-full-agonists-partial-agonists-and-inv erse-agonists 61. Dose-Response Relationships - Clinical Pharmacology - MSD Manual Professional Edition, accessed on November 4, 2025, https://www.msdmanuals.com/professional/clinical-pharmacology/pharmacodynamics/dose-response-rel ationships 62. Full agonists, partial agonists and inverse agonists - Deranged Physiology, accessed on November 4, 2025, https://derangedphysiology.com/main/cicm-primary-exam/pharmacodynamics/Chapter-417/full-agonists -partial-agonists-and-inverse-agonists 63. Pharmacological Glossary | Tocris Bioscience, accessed on November 4, 2025, https://www.tocris.com/resources/pharmacological-glossary 64. What is Buprenorphine? - UAMS Psychiatric Research Institute, accessed on November 4, 2025, https://psychiatry.uams.edu/clinical-care/outpatient-care/cast/buprenorphine/ 65. Buprenorphine - StatPearls - NCBI Bookshelf, accessed on November 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK459126/ 66. Competitive and non-competitive antagonists | Deranged Physiology, accessed on November 4, 2025, https://derangedphysiology.com/main/cicm-primary-exam/pharmacodynamics/Chapter-418/competitive- and-non-competitive-antagonists 67. 8. Two Main Classes of Receptor Ligands in Pharmacology ..., accessed on November 4, 2025, https://open.lib.umn.edu/pharmacology/chapter/two-main-classes-of-receptor-ligands-in-pharmacology-a gonists-antagonists/ 68. Non-competitive antagonist - Canadian Society of Pharmacology and Therapeutics (CSPT), accessed on November 4, 2025, https://pharmacologycanada.org/non-competitive-antagonist 69. Receptor antagonist - Wikipedia, accessed on November 4, 2025, https://en.wikipedia.org/wiki/Receptor_antagonist 70. Spare receptors | PPTX - Slideshare, accessed on November 4, 2025, https://www.slideshare.net/slideshow/spare-receptors/55127041 71. Canadian Society of Pharmacology and Therapeutics (CSPT ..., accessed on November 4, 2025, https://pharmacologycanada.org/spare-receptors 72. Adenosine Receptor Reserve and Long-Term Potentiation: Unconventional Adaptive Mechanisms in Cardiovascular Diseases? - PubMed Central, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8303608/ 73. Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists - PubMed, accessed on November 4, 2025, https://pubmed.ncbi.nlm.nih.gov/8584979/ 74. Dose–response relationship - Wikipedia, accessed on November 4, 2025, https://en.wikipedia.org/wiki/Dose%E2%80%93response_relationship 75. Effect of competitive antagonist on dose-response relationship - MSD Veterinary Manual, accessed on November 4, 2025, https://www.msdvetmanual.com/multimedia/image/effect-of-competitive-antagonist-on-dose-response-re lationship 76. Agonism and antagonism - Physics, Pharmacology and Physiology for Anaesthetists, accessed on November 4, 2025, https://www.cambridge.org/core/books/physics-pharmacology-and-physiology-for-anaesthetists/agonism -and-antagonism/CD663060E8B59243653755AD2925AA14 77. Tolerance | Research Starters - EBSCO, accessed on November 4, 2025, https://www.ebsco.com/research-starters/history/tolerance 78. Drug Tolerance and Tachyphylaxis | Anesthesiology Core Review - AccessAnesthesiology, accessed on November 4, 2025, https://accessanesthesiology.mhmedical.com/content.aspx?bookid=974§ionid=61587630 79. Understanding Dependence, Addiction, & Tolerance - Drug Free CT, accessed on November 4, 2025, https://www.drugfreect.org/treatment-and-recovery/understanding-dependence-addiction-and-tolerance/ 80. Tachyphylaxis and tolerance - Physics, Pharmacology and Physiology for Anaesthetists, accessed on November 4, 2025, https://www.cambridge.org/core/books/physics-pharmacology-and-physiology-for-anaesthetists/tachyph ylaxis-and-tolerance/4F886C44FEDA5F8274AD598EDAD55565 81. Metabolic drug tolerance - Canadian Society of Pharmacology and Therapeutics (CSPT), accessed on November 4, 2025, https://pharmacologycanada.org/Metabolic-drug-tolerance 82. Mechanisms of tolerance and tachyphylaxis | Deranged Physiology, accessed on November 4, 2025, https://derangedphysiology.com/main/cicm-primary-exam/variability-drug-response/Chapter-221/mecha nisms-tolerance-and-tachyphylaxis 83. Drug tolerance - Wikipedia, accessed on November 4, 2025, https://en.wikipedia.org/wiki/Drug_tolerance 84. Drug dependence is not addiction—and it matters - PMC - NIH, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8583742/ 85. Opioids: Understanding Addiction Versus Dependence - HSS, accessed on November 4, 2025, https://www.hss.edu/health-library/conditions-and-treatments/understanding-addiction-versus-dependenc e 86. Tolerance, Dependence, and Addiction. | Steve Rummler HOPE Network, accessed on November 4, 2025, http://steverummlerhopenetwork.org/tolerance-dependence-addiction/ 87. Idiosyncratic drug reactions - Deranged Physiology, accessed on November 4, 2025, https://derangedphysiology.com/main/cicm-primary-exam/variability-drug-response/Chapter-224/idiosy ncratic-drug-reactions 88. Adverse Drug Reactions: Types and Treatment Options | AAFP, accessed on November 4, 2025, https://www.aafp.org/pubs/afp/issues/2003/1101/p1781.html 89. Adverse Drug Reactions - StatPearls - NCBI Bookshelf, accessed on November 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK599521/ 90. Drug Allergy - Approach to the Patient - DynaMed, accessed on November 4, 2025, https://www.dynamed.com/approach-to/drug-allergy-approach-to-the-patient 91. Hypersensitivity, Overview of the Types, Animation. - YouTube, accessed on November 4, 2025, https://www.youtube.com/watch?v=jXTW4F-8jd4 92. Hypersensitivity - Wikipedia, accessed on November 4, 2025, https://en.wikipedia.org/wiki/Hypersensitivity 93. Type I Hypersensitivity Reaction - StatPearls - NCBI Bookshelf - NIH, accessed on November 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK560561/ 94. Drug Hypersensitivity: Diagnosis, Genetics, and Prevention - PMC - NIH, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6121083/ 95. Chapter 28: Classification of hypersensitivity reactions - PubMed, accessed on November 4, 2025, https://pubmed.ncbi.nlm.nih.gov/22794701/ 96. Idiosyncratic Adverse Drug Reactions: Current Concepts - PMC - PubMed Central, accessed on November 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3639727/